<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00658203</url>
  </required_header>
  <id_info>
    <org_study_id>CLEAR - IPEA01</org_study_id>
    <nct_id>NCT00658203</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation on Advanced Resynchronization</brief_title>
  <official_title>Clinical Evaluation on Advanced Resynchronization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LivaNova</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LivaNova</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to compare clinical benefits of the cardiac resynchronisation (CRT)
      achieved by the PEA optimised pacing configuration and a CRT optimised by standard clinical
      procedure.

      PEA optimised configuration (PEA-CRT) is obtained, during patient's follow-up, using the Peak
      Endocardial Acceleration sensor features onboard the device.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a prospective, multicentre, controlled and randomised clinical investigation,
      with two single-blinded arms.

      The objective of the study is to compare the clinical benefits of Cardiac Resynchronisation
      Therapy (CRT) optimised by automatic PEA sensor features (PEA-CRT), with those obtained by
      standard optimisation procedure (STD-CRT).

      The patient candidate for inclusion in the study has a severe chronic Heart Failure,
      indicated for the implantation of a Biventricular pacing system according to updated ESC
      guidelines (2005).

      All patients included in the study will be followed-up for 1 year; patient's follow-ups are
      scheduled during hospitalisation, at one month, 3 months, 6 months and one year after
      implantation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint will be evaluated at 1 year (M12), in term of improved, unchanged or worsened patient's conditions, with a composite analysis of NYHA class evolution, heart-failure-related hospitalisations and Quality of Life evaluation.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PEA-CRT optimisation is at least effective as the standard optimisation in term of efficacy of the therapy and patients' quality of life.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEA is an index of the patients' clinical status and allows to predict acute HF episode in both arms.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the therapy comparing the two arms in terms of NYHA</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the therapy comparing the two arms in terms of Cardiovascular mortality</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the therapy comparing the two arms in terms of Heart Failure Quality Of Life (EuroQoL-5D) score</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the therapy comparing the two arms in terms of BNP dosage</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the therapy comparing the two arms in terms of Number and duration of heart-failure-related patient's hospitalisations, during the study period.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the therapy comparing the two arms in terms of Left Ventricular End Diastolic Diameter</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the therapy comparing the two arms in terms of Left Ventricular End Systolic Diameter</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the therapy comparing the two arms in terms of Left Ventricular Ejection Fraction</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the therapy comparing the two arms in terms of Left Pre-Ejection Interval</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the therapy comparing the two arms in terms of Right Pre-Ejection Interval</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the therapy comparing the two arms in terms of Total Duration of Left Systole</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the therapy comparing the two arms in terms of E velocity</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the therapy comparing the two arms in terms of A velocity</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the therapy comparing the two arms in terms of Ventricular spike-Mitral valve closure interval</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the therapy comparing the two arms in terms of Ventricular spike-Mitral valve opening interval</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the therapy comparing the two arms in terms of Mitral Valve regurgitation.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time spent to achieve the CRT optimal configuration during each follow-up</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEA monitoring and prognostic relevance correlating the PEA diagnostic trends with the parameters used to asses the efficacy of the therapy and patients' quality of life (NYHA class, mortality, HF-hospitalisation, EuroQoL-5D score, BNP dosage, Echo</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(LVEF) comparing the changes Left Ventricular Ejection Fraction in the two arms with an intermediate analysis at 6 months done by a Core Centre.</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Heart Failure</condition>
  <condition>Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PEA optimized CRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard optimized CRT</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>New Living CHF</intervention_name>
    <description>PEA CRT optimization</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>New Living CHF</intervention_name>
    <description>Standard optimized CRT.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The patient candidate for inclusion in the study must be indicated for implantation of a
        Biventricular pacing system, with the following clinical conditions:

          -  Severe Heart Failure (NYHA Class III or IV)

          -  Cardiomyopathy of any etiology

          -  Sinus rhythm

          -  Reduced Left-Ventricular Ejection Fraction

          -  Left-Ventricular End Diastolic Diameter greater than or equal to 30 mm/m2 (LVEDD&gt;30
             mm/m2)

          -  QRS Duration:

               -  &gt; 150 ms or

               -  &gt; 120 ms and documented Mechanical Dissynchrony (by ECHO) meeting two out of
                  three of the following criteria:

                    -  Aortic Pre-Ejection Delay &gt; 140 ms

                    -  Interventricular Mechanical Delay &gt; 40 ms

                    -  Delayed activation of postero-lateral Left Ventricular wall (after mitral
                       valve opening)

          -  Optimal and stable (1 month before inclusion) pharmacological treatment, including, if
             tolerated, Beta Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors or ACE
             Inhibitor substitutes, Spironolactone, and diuretics

        Exclusion Criteria:

        Any patient who has one of the following characteristics will be excluded from the study:

          -  ICD indication (Life-threatening ventricular arrhythmias)

          -  Persistent or permanent Atrial Arrhythmia without possibility to restore sinus rhythm
             (spontaneous termination, anti-tachycardia pacing, pharmacological or electrical
             cardioversion).

          -  Patient already implanted with a conventional pacemaker device

          -  Myocardial infarction within the last three months

          -  Heart surgery, or revascularization within the last three months, or expected

          -  Heart surgery refused because of co-morbidity factors

          -  Included in transplantation list

          -  Already enrolled in other study

          -  Life expectancy less than 1 year

          -  Pregnancy

          -  Age less than 18

          -  Forfeiture of freedom or under guardianship

          -  Not able to understand the aim of the study and its procedures

          -  Refusing to cooperate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>P Ritter, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>InParys Cardiologie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CH Albi</name>
      <address>
        <city>Albi</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Lomme</name>
      <address>
        <city>Lomme</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NC Nantaises</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Pau</name>
      <address>
        <city>Pau</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR Cardiologie A</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Yves le Foll</name>
      <address>
        <city>Saint-Brieuc</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InParys Cardiology</name>
      <address>
        <city>St Cloud</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UKB Unfallkrankenhaus</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ Saarland</name>
      <address>
        <city>Homburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stiftsklinikum Augustinum</name>
      <address>
        <city>Munchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.Adolfstift</name>
      <address>
        <city>Reinbek</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osp. B. Ramazzini</name>
      <address>
        <city>Carpi</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osp. Civile</name>
      <address>
        <city>Desio</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osp. S. Maria Nuova</name>
      <address>
        <city>Florence</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osp. Univ. Careggi</name>
      <address>
        <city>Florence</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osp. Niguarda</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osp. Civile</name>
      <address>
        <city>Rieti</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osp. S. Filippo Neri</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Rijnmond-Zuid</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diaconessenhuis</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vlietland Ziekenhuis</name>
      <address>
        <city>Vlaardingen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. General Universit.</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. General Universit.</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Clinico</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hospital</name>
      <address>
        <city>Bournemouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Peter's Hospital</name>
      <address>
        <city>Chertsey</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital</name>
      <address>
        <city>Eastbourne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nothern General</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2008</study_first_submitted>
  <study_first_submitted_qc>April 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2008</study_first_posted>
  <last_update_submitted>April 7, 2008</last_update_submitted>
  <last_update_submitted_qc>April 7, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2008</last_update_posted>
  <responsible_party>
    <name_title>P. RITTER - Principal investigator</name_title>
    <organization>InParys</organization>
  </responsible_party>
  <keyword>CRT-P</keyword>
  <keyword>PEA</keyword>
  <keyword>Severe Heart Failure (NYHA Class III or IV)</keyword>
  <keyword>Cardiomyopathy of any etiology</keyword>
  <keyword>Sinus rhythm</keyword>
  <keyword>Reduced Left-Ventricular Ejection Fraction</keyword>
  <keyword>LVEDD&gt;30 mm/m2</keyword>
  <keyword>QRS Duration: &gt; 150 ms or &gt; 120 ms</keyword>
  <keyword>Aortic Pre-Ejection Delay &gt; 140 ms</keyword>
  <keyword>Interventricular Mechanical Delay &gt; 40 ms</keyword>
  <keyword>Delayed activation of postero-lateral Left Ventricular wall</keyword>
  <keyword>Optimal and stable pharmacological treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

